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Abstract
Control of HIV replication is a rare immunological event, providing clues to understand the
viral control mechanism. CD8+ T-cell responses are crucial for virus control, but it is unclear
whether lasting HIV containment can be achieved after establishment of infection. Here, we
describe lasting SIV containment in a macaque AIDS model. Analysis of ten rhesus
macaques that controlled viremia for 2 years post-infection found accumulation of proviral
gag and nef CD8+ T-cell escape mutations in four of them. These four controllers mounted
CD8+ T cells targeting Gag, Nef, and other viral proteins at 4 months, suggesting that broad-
ening of CD8+ T-cell targets can be an indicator of the beginning of viral control failure. The
remaining six aviremic SIV controllers, however, harbored proviruses without mutations
and showed no or little broadening of their CD8+ T-cell responses in the chronic phase.
Indeed, three of the latter six exhibiting no change in CD8+ T-cell targets showed gradual
decreases in SIV-specific CD8+ T-cell frequencies, implying a concomitant reduction in viral
replication. Thus, stability of the breadth of virus-specific CD8+ T-cell responses may repre-
sent a status of lasting HIV containment by CD8+ T cells.
Author Summary
CD8+ T-cell responses are crucial for HIV control, but it is unclear whether lasting HIV
containment can be achieved after establishment of infection. Several T cell-based vaccine
trials have currently shown primary viremia control in macaque AIDS models of simian
immunodeficiency virus (SIV) infection, but residual viral replication may occur, followed
by accumulation of viral CD8+ T-cell escape mutations, possibly leading to eventual vire-
mia rebound. In the present study, we analyzed ten rhesus macaques that controlled SIV
replication without detectable viremia for more than 2 years. Animals were divided into
two groups on the basis of proviral genome sequences at 2 years post-infection. Analysis
of the first group exhibiting multiple CD8+ T-cell escape mutations indicated that
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broadening of CD8+ T-cell responses can be an indicator of the beginning of viral control
failure. Conversely, analysis of the second group having no mutation suggested that stabil-
ity of the breadth of virus-specific CD8+ T-cell responses represents a status of lasting HIV
containment by CD8+ T cells. Thus, this study presents a model of stable SIV containment,
contributing to elucidation of the requisites for lasting HIV control.
Introduction
Human immunodeficiency virus (HIV) and simian immunodeficiency virus (SIV) infection
induces chronic, persistent viral replication leading to AIDS onset in humans and rhesus
macaques, respectively. While antiretroviral therapy (ART) has reduced the morbidity and
mortality due to HIV, it does not cure infection. Much effort has been made aiming at inducing
a functional cure, defined as HIV containment with cessation of ART [1–4]. A current trial of
administration with a monoclonal broadly reactive neutralizing antibody under ART showed a
longer aviremic period but eventual rebound viremia after ART interruption in rhesus
macaques [5,6].
Virus-specific CD8+ T cells exert strong suppressive pressure on HIV/SIV replication [7–
11], but fail to control viremia in most infections. Studies of HIV-infected individuals have
revealed the association of certain HLA or major histocompatibility complex (MHC) class I
genotypes with lower viral loads [12–15]. In the Indian rhesus macaque AIDS model, animals
possessing protective MHC alleles such asMamu-B08 andMamu-B17 tend to show slower
disease progression after SIVmac251/SIVmac239 infection [16–18]. CD8+ T-cell responses
restricted by these HLA/MHC molecules have been shown to be responsible for HIV/SIV con-
trol in most studies [15,19–21]. However, aviremic HIV/SIV control is rare, and even in those
with undetectable viremia, residual viral replication can occur and allow accumulation of viral
genome mutations resulting in viral escape from CD8+ T-cell recognition, possibly leading to
eventual viremia rebound [22–25].
Several prophylactic T cell-based vaccine trials have currently shown primary viremia con-
trol in macaque AIDS models [26–29]. However, it is difficult to obtain sterile protection from
virus infection by T cell-based vaccines, and whether vaccine-based, primary non-sterile viral
control can be stably maintained is debatable. Analysis of those rare cases exhibiting aviremic
HIV/SIV control may provide clues to the development of a novel intervention resulting in
lasting HIV control.
We previously developed a prophylactic AIDS vaccine using a DNA prime and a boost with a
Sendai virus (SeV) vector expressing SIVmac239 Gag (SeV-Gag) [26,30]. Our trial showed vac-
cine-based control of an SIVmac239 challenge in a group of Burmese rhesus macaques sharing
the MHC class I haplotype 90-120-Ia (referred to as A+ animals) [31]. TheMamu-A1043:01,
Mamu-A1065:01,Mamu-B061:03,Mamu-B068:04, andMamu-B089:01 alleles have been
confirmed in this haplotype [32,33]. Two-thirds of unvaccinated A+ animals showed persistent
viremia after SIVmac239 infection, whereas all the A+ animals vaccinated with a DNA prime
and an SeV-Gag boost controlled SIV replication without detectable viremia at 2 months post-
challenge [31,33]. CD8+ T-cell responses specific for dominant Mamu-A1043:01 (GenBank
accession number AB444869)-restricted Gag206–216 (IINEEAADWDL) and Mamu-A1065:01
(AB444921)-restricted Gag241–249 (SSVDEQIQW) epitopes are responsible for this vaccine-
based SIV control [31]. However, two of these SIV controllers accumulated multiple gag CD8+
T-cell escape mutations and plasma viremia reappeared after 1 year of SIV control [25].
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In the present study, we analyzed ten A+ animals that controlled viremia for 2 years after
SIVmac239 challenge to determine whether such non-sterile aviremic SIV control can be stably
maintained. Four of these ten SIV controllers exhibited an accumulation of proviral CD8+ T-
cell escape mutations, indicating the latent viral control failure with preceding broadening of
SIV-specific CD8+ T-cell targets. In contrast, the remaining six controllers showed no proviral
mutations with little change in CD8+ T-cell targets in the chronic phase. Three of the latter six
showed a gradual reduction in SIV-specific CD8+ T-cell frequencies, implying stable non-ster-
ile SIV control with waning viral replication. These results suggest a possible achievement of
lasting SIV containment by CD8+ T cells without transition of their targets.
Results
Proviral sequences in SIV controllers
Ten Burmese rhesus macaques possessing the MHC class I haplotype 90-120-Ia that controlled
viremia for 2 years after SIVmac239 challenge were studied. In our previous study [34], most
A+ animals mounted Gag-specific and Nef-specific CD8+ T-cell responses in primary SIV-
mac239 infection. Seven 90-120-Ia-associated CD8+ T-cell epitopes, Gag206–216, Gag241–249,
Gag367–381, Nef9–19, Nef89–97, Nef193–203, and Vif114–124, in SIVmac239 antigens have been iden-
tified, and unvaccinated A+ animals that failed to control viral replication have been shown to
select viral escape mutations from all of these epitope-specific CD8+ T cells within a year after
SIVmac239 challenge [25,33,34]. Ten SIV controllers used in the present study consisted of
two unvaccinated, one sham-vaccinated, and seven vaccinated A+ animals as shown in Table 1.
Three macaques (R07-002, R07-003, and R07-008) were immunized with a single Gag241–249-
epitope vaccine expressing the Gag241–249 epitope fused with enhanced green fluorescent pro-
tein (EGFP) [35], three macaques (R03-018, R09-009, and R09-010) with a single Gag206–216-
epitope vaccine expressing the Gag206–216 epitope fused with EGFP [36], and macaque R05-005
Table 1. SIV controllers analyzed in this study













aAnimals were unvaccinated or vaccinated with DNA-prime/SeV-boost expressing EGFP (control), Gag202–
216-EGFP and Gag236–251-EGFP (Gag206–216/241–249), Gag236–251-EGFP (Gag241–249), or Gag202–216-EGFP
(Gag206–216) before SIVmac239 challenge. All of them controlled SIV replication for more than 2 years.
bpositive, viral gag fragments were detected by RT-PCR amplification from culture supernatant-derived
RNAs of PBMCs at 2 years; negative, those were undetectable.
cOn the basis of the data on proviral gag nucleotide sequences at 2 years post-infection, animals were
divided into two groups, Group M with multiple mutations and Group N with no mutation.
doi:10.1371/journal.ppat.1005247.t001
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with a mixture of both. In these vaccinated animals, plasma viremia became undetectable at 2
months post-infection, whereas unvaccinated controllers showed undetectable viremia after 6
months (Fig 1A). All the animals controlled SIV replication until 2 years, but two of them
(R05-005 and R03-018) clearly exhibited reappearance of plasma viremia after that (Fig 1A).
Viremia was undetectable at 1 year post-infection in all the ten SIV controllers even by quanti-
tation of viral loads using fivefold-concentrated plasma (Table 2). However, this higher-sensi-
tive assay detected marginal levels of viremia at 2 years post-infection in macaques R05-005
Fig 1. Plasma viral loads and peripheral %CD4 in SIV controllers. (A) Plasma viral loads (SIV gag RNA copies/ml plasma) determined as described
previously [26]. The lower limit of detection is approximately 4 x 102 copies/ml. On the basis of the data on proviral gag nucleotide sequences at 2 years post-
infection, animals were divided into two groups, Group M (M) with multiple CD8+ T-cell escape mutations and Group N (N) with no mutation. (B) Percentage
of CD4+ T cells in PBMCs.
doi:10.1371/journal.ppat.1005247.g001
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and R03-018 (Table 2). Peripheral CD4+ T lymphocytes were maintained in all of these SIV
controllers (Fig 1B).
We examined whether viral gag CD8+ T-cell escape mutations accumulated during SIV con-
trol. Plasma viral loads were too low for us to recover viral gag cDNA fragments by reverse
transcription (RT) and nested PCR amplification from concentrated plasma-derived RNA of
these SIV controllers during the chronic phase of infection. We, therefore, analyzed sequences
of proviral gag cDNA fragments amplified by nested PCR. Template DNAs were extracted
from CD4+ T cells isolated from macaque peripheral blood mononuclear cells (PBMCs)
obtained at approximately 2 years post-infection (Fig 2). Four animals (referred to as Group M
[Table 1]) had multiple proviral gagmutations, exhibiting the accumulation of CD8+ T-cell
escape mutations in the chronic phase. All Group M animals showed selection of mutations in
Gag206–216, Gag241–249, and Gag367–381 epitope-coding regions with additional gagmutations.
We have previously reported that the L216S (leading to a L-to-S substitution at the 216th
amino acid [aa] in Gag) and D205E (D-to-E at the 205th) mutations result in escape from
Gag206–216-specific CD8
+ T-cell recognition [25,37]. We have also confirmed that D244E (D-
to-E at the 244th) results in escape from Gag241–249-specific CD8
+ T cells and that A373T (A-
to-T at the 373rd) and V375M (V-to-M at the 375th) from Gag367–381-specific CD8
+ T cells
[25]. In contrast, the remaining six SIV controllers (referred to as Group N [Table 1]) showed
no proviral mutations in Gag206–216, Gag241–249, and Gag367–381 epitope-coding regions. No
mutation in other gag region was found in Group N animals except for macaque R09-010 hav-
ing a single M424T mutation. Viral gag cDNA fragments were amplified from culture superna-
tants of CD4+ T cells derived from three of four Group M animals but not from Group N
animals except for macaque R07-006 (Table 1), implying inefficient transcription or replication
capacity of the proviruses with no gagmutations in Group N animals.
We also analyzed proviral gag sequences in PBMCs obtained at 2 months and 1 year after
SIVmac239 challenge (Fig 2). In contrast to the results obtained at 2 years post-infection, no
proviral gagmutations were observed in Group M or Group N animals, except macaque R03-
018 (Group M) having a single L216S mutation at 1 year. Thus, Group Mmacaques accumu-
lated proviruses with multiple CD8+ T-cell escape mutations later than 1 year post-infection
and had replication-competent viruses that could be recovered from PBMC culture at 2 years.
Table 2. Plasma viral loads determined by using fivefold-concentrated plasmaa
Macaques VL at 1 year pi VL at 2 years pi
R06-037 undetectable ND
R05-005 undetectable 3.3 x 102 copies/ml
R07-002 undetectable undetectable







aAfter centrifugation of 1 ml of plasma at 25,000 x g for 2 hours, 0.8 ml of its supernatant was discarded for
fivefold concentration of plasma. The remaining 0.2 ml was subjected to RNA extraction for quantitation of
viral loads (VL) [25]. Plasma samples of R06-037 and R07-006 at 2 years post-infection (pi) were
unavailable (ND, not determined).
doi:10.1371/journal.ppat.1005247.t002
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We then examined proviral vif and nef sequences at 2 years in these SIV controllers (Fig 3).
Proviral vif cDNA fragments were amplified from three of four Group M and five of six Group
N animals. Proviral vifmutations were found in two of the three Group M but only one of the
five Group N. Neither Group M nor N had mutations in the Vif114–124 CD8
+ T-cell epitope-
coding region.
Group M animals had multiple proviral nefmutations, exhibiting accumulation of CD8+ T-
cell escape mutations during the chronic phase of infection. Mutations in the Nef9–19- and
Fig 2. Dominant non-synonymousmutations in proviral gag in SIV controllers. Amino acid substitutions around SIV Gag206–216, Gag241–249, and
Gag367–381 epitopes and in other Gag regions approximately 2 months (2M, top), 1 year (1Y, middle), and 2 years (2Y, bottom) after SIVmac239 challenge
are shown. Most of the proviral gag fragments were amplified from CD4+ T cells isolated from PBMCs, while those at 2 years in macaques R06-037, R05-
005, R07-001, and R07-006 were from cultured CD4+ T cells due to limitation of available cell numbers. Mutant sequences shown were completely dominant
(i.e., wild-type sequences were undetectable at the residues showing mutant sequences) except for the L216Smutation (the ratio of wild type/mutant: 2/5) in
macaque R03-018 at 1 year post-infection. No subdominant mutation was detected.
doi:10.1371/journal.ppat.1005247.g002
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Nef89–97-coding regions were selected in three and two of four Group M animals, respectively.
We have previously reported that the P12T (P-to-T at the 12th aa in Nef) and S13P (S-to-P at
the 13th) were Nef9–19-specific CD8
+ T-cell escape mutations [34]. In the Nef193–203-coding
region, however, no mutation was observed even in Group M animals. In contrast, Group N
controllers showed no mutation in proviral Nef9–19- Nef89–97- and Nef193–203-coding regions,
while macaques R07-001 and R07-003 had multiple G-to-A mutations (S1 Fig), possibly due to
the effect of the APOBEC3 family [38–41]. Thus, we found two groups of A+ SIV controllers,
Group M accumulating CD8+ T-cell escape mutations and Group N having no dominant
CD8+ T-cell escape mutations in proviruses.
SIV antigen-specific CD8+ T-cell responses in SIV controllers
Next, we examined individual SIV antigen-specific CD8+ T-cell responses in our SIV control-
lers by using panels of overlapping peptides spanning the entire SIVmac239 Gag, Pol, Vif, Vpx,
Vpr, Tat, Rev, Env, and Nef amino acid sequences (Fig 4A). No significant difference in SIV
Fig 3. Dominant non-synonymousmutations in proviral vif and nef in SIV controllers. In the upper panel, amino acid substitutions around SIV Vif114–
124 epitope and in other Vif regions approximately 2 years after SIVmac239 challenge are shown. In the lower panel, amino acid substitutions around SIV
Nef9–19, Nef89–97, and Nef193–203 epitopes and in other Nef regions approximately 2 years after SIVmac239 challenge are shown. Sequences of vif in
macaques R03-018 and R07-008 and nef in macaques R07-008 were not determined because these cDNA fragments could not be amplified. Macaques
R07-001 and R07-003 had multiple G-to-A mutations in nef (See S1 Fig). Mutant sequences shown were completely dominant except for vif P138L (the ratio
of wild type/mutant: 1/2) in R05-005, vifQ162R (1/1) in R07-006, nef P012T (1/10) in R06-037, and nef S013P (3/10), I090T (1/5), D096N (1/5), and E191K
(1/5) in R07-002. In addition, subdominant nefmutations resulting in P012S (5/2) and G044E (5/2) were detected in macaque R07-002, while the wild-type
sequences were dominant at these positions.
doi:10.1371/journal.ppat.1005247.g003
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Fig 4. SIV antigen-specific CD8+ T-cell responses in SIV controllers. (A) Frequencies of CD8+ T cells specific for Gag, Nef, Vif, Vpx, Vpr, Tat, Rev, Pol,
and Env in Group M (upper panels) and Group N (lower) at 4 months (4M), 1 year (1Y), and 2 years (2Y) post-infection. Responses were measured by
detection of antigen-specific IFN-γ induction using panels of overlapping peptides spanning the entire SIVmac239 Gag, Nef, Vif, Vpx, Vpr, Tat, Rev, Pol, and
Env amino acid sequences, respectively. (B) Comparisons of CD8+ T-cell frequencies specific for SIV antigens other than Gag and Nef at 4M, 1Y, and 2Y
between Groups M and N. Group M had significantly higher frequencies of SIV non-Gag/Nef antigen-specific CD8+ T cells at 4M (p = 0.0095 by Mann-
Whitney U-test) and 1Y (p = 0.0095). (C) Comparisons of the numbers of CD8+ T cell-targeted SIV antigens other than Gag and Nef at 4M, 1Y, and 2Y
between Groups M and N. The numbers were significantly higher in Group M at 4M (p = 0.0095 by Mann-Whitney U-test) and 1Y (p = 0.0095).
doi:10.1371/journal.ppat.1005247.g004
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whole antigen-specific CD8+ T-cell frequencies (sum of individual antigen specific CD8+ T-cell
frequencies) was observed between Groups M and N at 4 months post-infection. However, the
frequencies in Group M were significantly higher than in Group N at 1 year post-infection
(p = 0.0381 by Mann-Whitney U-test). All the Group M animals had higher frequencies at 1
year than at 4 months, but Group N showed no or minimal increase in the whole antigen-spe-
cific CD8+ T-cell frequencies. In particular, three Group N controllers, R07-008, R09-009, and
R09-010, exhibited gradual decreases in the whole antigen-specific CD8+ T-cell frequencies
from 4 months to 2 years following challenge (Fig 4A).
All the A+ SIV controllers induced predominant Gag- and/or Nef-specific CD8+ T-cell
responses at 4 months after SIVmac239 infection (Fig 4A). Group M animals elicited addi-
tional CD8+ T-cell responses directed against SIV antigens other than Gag and Nef. These SIV
non-Gag/Nef antigen-specific CD8+ T-cell frequencies were significantly higher in Group M
than those in Group N at 4 months (p = 0.0095 by Mann-Whitney U-test) and 1 year
(p = 0.0095) (Fig 4B). Indeed, the numbers of SIV non-Gag/Nef antigens targeted by CD8+ T
cells were significantly higher in Group M than those in Group N at 4 months (p = 0.0095 by
Mann-Whitney U-test) and 1 year (p = 0.0095) (Fig 4C). All the Group M animals showed
increase in the numbers of SIV antigens targeted by CD8+ T cells at 1 year compared to those
at 4 months. In particular, SIV non-Gag antigen-specific CD8+ T-cell frequencies were signifi-
cantly higher in Group M at 1 year (p = 0.0087). These results indicate the broadening of the
CD8+ T-cell response in Group M.
All four animals in Group Mmounted CD8+ T-cell responses specific for SIV non-Gag/Nef
antigens, which were undetectable in all Group N animals at 4 months post-infection. Also at 1
year, all of the animals in Group M showed CD8+ T-cell responses specific for several targets
besides the Gag and Nef antigens. In contrast, only Gag-specific and Nef-specific CD8+ T-cell
responses were observed in Group N animals except for macaque R07-003 which had detect-
able Vif-specific CD8+ T-cell responses. At 2 years post-infection, Vif-specific CD8+ T-cell
responses were detected in three macaques in Group N, while the remaining three showed
Gag-specific and Nef-specific CD8+ T-cell responses only. Importantly, the latter three
macaques (R07-008, R09-009, and R09-010) exhibited gradual decreases in these Gag/Nef-spe-
cific CD8+ T-cell responses in the chronic phase, possibly reflecting the absence of measurable
viral replication.
SIV epitope-specific CD8+ T-cell responses in SIV controllers
We further examined CD8+ T-cell responses specific for 90-120-Ia-associated Gag epitopes;
Gag206–216, Gag241–249, and Gag367–381, in the ten SIV controllers (Fig 5A). The sum of these
Gag epitope-specific CD8+ T-cell frequencies was similar between Groups M and N (Fig 5B).
Induction of CD8+ T-cell responses directed against both dominant Gag206–216 and Gag241–249
epitopes were confirmed in all the animals in previous analyses at weeks 2 and 12 post-infec-
tion [35,36]. At 4 months, all had detectable Gag241–249-specific CD8
+ T cells, although Gag206–
216-specific CD8
+ T-cell responses were undetectable in three animals. However, at 2 years
post-infection, the Gag241–249-specific CD8
+ T-cell responses became undetectable in three of
four Group M animals but were maintained in Group N animals except for macaque R09-010
which exhibited Gag206–216-specific CD8
+ T-cell responses.
We also examined CD8+ T-cell responses specific for 90-120-Ia-associated Nef9–19, Nef89–
97, Nef193–203, and Vif114–124 epitopes in the SIV controllers (Fig 6A). In most of the animals
immunized with Gag241–249-epitope and/or Gag206–216-epitope vaccines (except for macaque
R09-009), these Gag epitope-specific CD8+ T-cell responses were predominant but Nef/Vif epi-
tope-specific CD8+ T-cell responses were undetectable at 4 months post-challenge. At 1 and 2
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years post-infection, differences in these Nef/Vif epitope-specific CD8+ T-cell responses
between Groups M and N became evident. All the Group M animals mounted Nef9–19- Nef89–
97-, or Nef193–203-specific CD8
+ T-cell responses at 1 year and Vif114–124-specific CD8
+ T-cell
responses at 2 years post-infection. In contrast, none of the Group N animals elicited Vif114–
124-specific CD8
+ T-cell responses. In two of them, macaques R07-008 and R09-010, even
Nef9–19- Nef89–97-, and Nef193–203-specific CD8
+ T cells were undetectable. Indeed, the sum of
Nef9–19- Nef89–97-, Nef193–203-, and Vif114–124-specific CD8
+ T-cell frequencies in Group M
was significantly higher than in Group N at 2 years (p = 0.0190 by Mann-Whitney U-test) (Fig
6B). Thus, Group M animals mounted Nef and Vif epitope-specific CD8+ T-cell responses in
the chronic phase of infection, whereas such broadening of CD8+ T-cell responses was unclear
and Gag epitope-specific CD8+ T cells were maintained in Group N. In particular, in three of
Fig 5. Gag206–216, Gag241–249, and Gag367–381 epitope-specific CD8
+ T-cell responses in SIV controllers. (A) Frequencies of CD8+ T cells specific for
SIV Gag206–216, Gag241–249, and Gag367–381 epitopes in Group M (upper panels) and Group N (lower) at 4 months (4M), 1 year (1Y), and 2 years (2Y) post-
infection. (B) Comparisons of the sum of Gag206–216-, Gag241–249-, and Gag367–381-specific CD8
+ T-cell frequencies at 4M, 1Y, and 2Y between Groups M
and N. No significant difference was observed between the groups.
doi:10.1371/journal.ppat.1005247.g005
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six Group N macaques, R07-008, R09-009, and R09-010, comparison between 4 months and 2
years post-challenge showed no change in CD8+ T-cell target epitopes.
CD8+ cell-depletion in a Group N controller
Three of six Group N controllers, R07-008, R09-009, and R09-010, showed gradual decreases
and stable breadth in the SIV antigen-specific CD8+ T-cell responses from 4 months to 2 years
post-infection. To confirm involvement of the CD8+ T-cell responses in this stable SIV control,
we administered an anti-CD8 antibody to deplete the CD8+ cells in macaque R09-009 2 years
following challenge. Peripheral CD8+ T cells were undetectable for approximately 2 weeks
from day 3 after the initial anti-CD8 antibody administration at week 108 post-infection and
became detectable at week 111 (Fig 7A). Plasma viremia was detectable for approximately 3
Fig 6. Nef9–19, Nef89–97, Nef193–203, and Vif114–124 epitope-specific CD8
+ T-cell responses in SIV controllers. (A) Frequencies of CD8+ T cells specific for
SIV Nef9–19, Nef89–97, Nef193–203, and Vif114–124 epitopes in Group M (upper panels) and Group N (lower) at 4 months (4M), 1 year (1Y), and 2 years (2Y)
post-infection. (B) Comparisons of the sum of Nef9–19-, Nef89–97-, Nef193–203-, and Vif114–124-specific CD8
+ T-cell frequencies at 4M, 1Y, and 2Y between
Groups M and N. The sum of CD8+ T-cell frequencies specific for these epitopes in Group M was significantly higher compared to Group N at 2Y post-
infection (p = 0.0190 by Mann-Whitney U-test).
doi:10.1371/journal.ppat.1005247.g006
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weeks from day 3 after the initial anti-CD8 antibody administration and became undetectable
at week 112 (Fig 7B). This transient reappearance of plasma viremia concomitant with CD8+
cell depletion supports the notion that CD8+ T-cell responses are crucial for the stable SIV
containment.
Macaque R09-009 showed Gag- and Nef-specific but not non-Gag/Nef antigen-specific
CD8+ T-cell responses before the anti-CD8 antibody administration at week 108 post-infection
(Fig 4A). Interestingly, however, this animal mounted high magnitude Vif-specific CD8+ T-cell
Fig 7. Virological and immunological analyses in macaque R09-009 following CD8+ cell depletion. (A) Changes in peripheral CD8+ T-cell counts after
the initial anti-CD8 antibody administration. Group Nmacaque, R09-009, was administered anti-CD8 antibody at week 108 post-infection and on days 3, 7,
and 10 after the first administration. (B) Changes in plasma viral loads. (C) Changes in CD8+ T-cell responses specific for SIV Gag, Nef, Vif, Vpx, Vpr, Tat,
Rev, Pol, and Env. (D) CD8+ T-cell responses specific for SIV Gag206–216, Gag241–249, Gag367–381, Vif114–124, Nef9–19, Nef89–97, and Nef193–203 epitopes at
week 113 post-infection. (E) Dominant non-synonymous mutations in plasma viral cDNA regions encoding Gag, Vif, and Nef epitopes. Viral gag, vif, and nef
cDNA fragments were amplified from plasma RNA obtained at weeks 110 and 118 post-infection. Amino acid substitutions around SIV Gag206–216, Gag241–
249, Gag367–381, Vif114–124, Nef9–19, Nef89–97, and Nef193–203 epitopes are shown.
doi:10.1371/journal.ppat.1005247.g007
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responses in the CD8+ T-cell recovery phase from week 111 post-infection (Fig 7C). Analysis
at week 115 detected no or poor Gag/Nef epitope-specific CD8+ T cells but dominant Vif114–
124 epitope-specific CD8
+ T-cell responses (Fig 7D). The plasma-derived viral genome cDNAs
at week 110 post-infection had mutations L216S in the Gag206–216 epitope-coding region,
D244E in Gag241–249, V375M in Gag367–381, S13P in Nef9–19, I90R in Nef89–97, and S201F in
Nef193–203 (Fig 7E). However, no mutation was detected in the Vif114–124 epitope-coding
region. Plasma viremia re-appeared at week 118, and the viruses at week 118 showed the simi-
lar pattern of sequences (Fig 7E). Thus, even in lasting aviremic SIV controllers, replication-
competent viruses with multiple CD8+ T-cell escape mutations may exist.
Discussion
In the present study, we examined ten rhesus macaques that controlled SIV replication without
detectable viremia for more than 2 years after infection. Four of these aviremic SIV controllers,
Group M, exhibited proviruses with multiple proviral CD8+ T-cell escape mutations in the
chronic phase, whereas the remaining six, Group N, had no proviral CD8+ T-cell escape muta-
tions. Three of six Group N animals showed a decline in SIV-specific CD8+ T-cell frequencies,
implying lasting non-sterile SIV control with a concomitant reduction in viral replication.
Although the size and character of virus reservoirs may be different from those under ART
[42,43], a rhesus cytomegalovirus (rhCMV) vector vaccine trial indicated lasting, non-sterile
SIV control by persistent rhCMV-induced CD8+ T-cell responses, possibly resulting in virus
clearance [44]. Our results suggest possible achievement of lasting SIV control by CD8+ T cells
without persistent exogenous stimulation. We were unable to find the genetic determinants for
the difference in the Groups M and N by analyses of their second MHC class I haplotypes
(Table 3), but this study presents a model of SIV containment, contributing to elucidation of
the requisites for lasting, non-sterile HIV control.
This study analyzed SIV controllers possessing the MHC-I haplotype 90-120-Ia. In our pre-
vious study [31], all the A+ animals vaccinated with a DNA prime and an SeV-Gag boost con-
trolled replication of the wild-type SIVmac239, whereas those that received the same vaccine
regimen failed to control a challenge with SIV carrying Gag206–216- and Gag241–249-specific
CD8+ T-cell escape mutations. Thus, these A+ animals are useful to examine the mechanism of
SIV control by CD8+ T cells, and the present study using these SIV controllers may provide a
clue to understand the mechanism for lasting SIV control. Analysis of CD8+ T cell-mediated
Table 3. Alleles in the secondMHC-I haplotypes in macaquesa
Macaques Alleles
R06-037 A1*052:01, A2*05:13, B*089:02/03
R05-005 A1*105:02, B*056:03, B*066:01
R07-002 A1*066:01, B*021:02
R03-018 A1*018:08, A2*05:31, B*001:01, B*007:02/03
R07-001 A1*032:02, B*066:01
R07-006 A1*032:02
R07-003 A1*066:01, B*003:01, B*005:01, B*007:02/03, B*015:04
R07-008 A1*004:01, A1*018:01, A2*05:31, B*043:01
R09-009 A1*107:01, B*046:03
R09-010 B*063:02, B*066:01
aDetected alleles not included in the first MHC-I haplotype 90-120-Ia are shown.
doi:10.1371/journal.ppat.1005247.t003
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SIV control needs animals sharing MHC-I genotypes like A+ macaques. If we could accumulate
long-lasting aviremic SIV controllers sharing other MHC-I alleles, although not easy, it would
contribute to our further understanding of viral control mechanism.
Gag206–216- and Gag241–249-specific CD8
+ T-cell responses played a central role in primary
viral control in these A+ SIV controllers as shown previously [31, 35,36]. In most vaccine-
based controllers, a viral CD8+ T-cell escape GagL216S mutation was rapidly selected and
plasma viremia became undetectable after 5 weeks of infection. However, the wild-type
sequence but not this CD8+ T-cell escape mutation was predominant in PBMC-derived provi-
ruses at 2 months post-infection, reflecting containment of the rapidly-selected mutant viruses.
The data infer that the detected proviruses with wild-type gag were maintained without eradi-
cation because of inefficient replication. Indeed, no virus was recovered from PBMC cultures
in most Group N animals (Table 1). How these proviruses became non-functional remains
unclear [45,46], but two Group N animals showed multiple G-to-A mutations in proviral nef
(S1 Fig), possibly reflecting an effect of the APOBEC3 family [38–41].
Two years after infection, animals in Group M showed multiple CD8+ T-cell escape muta-
tions in proviral gag and nef, suggesting replication of viruses carrying multiple mutations. In
our previous study [33], all the four MHC-I haplotype 90-120-Ia-positive macaques that failed
to control SIVmac239 replication showed CD8+ T-cell responses targeting SIV non-Gag/Nef
as well as Gag/Nef antigens at 3 months and/or 1 year post-infection. In all of these animals,
analysis of plasma RNA-derived viral genome sequences at 1 year post-infection found pre-
dominant nonsynonymous mutations in all the seven regions encoding SIV Gag206–216,
Gag241–249, Gag367–381, Vif114–124, Nef9–19, Nef89–97, and Nef193–203 epitopes, respectively. In the
present study, analysis of these MHC-I haplotype 90-120-Ia-associated epitopes at 2 years
showed Gag206–216, Gag241–249, and Gag367–381 epitope-specific CD8
+ T-cell escape mutations
in all Group M animals. Nef9–19-specific CD8
+ T-cell escape mutations were also selected in
most of them. However, mutations were not observed in Nef193–203 or Vif114–124 epitope-cod-
ing region. At 2 years after infection, only one of four Group M animals maintained Gag206–
216/Gag241–249-specific CD8
+ T cells, whereas all elicited Nef193–203 and Vif114–124 epitope-spe-
cific CD8+ T-cell responses, implying that these CD8+ T cells targeting Nef193–203 and Vif114–
124 epitopes may contribute to sustained control of viremia in Group M animals.
These results suggest undetectable level of viral replication in Group M animals, resulting in
accumulation of CD8+ T-cell escape mutations during viremia control. Higher SIV-specific
CD8+ T-cell frequencies and broadening of the CD8+ T-cell targets in this group are considered
to reflect this undetectable level of viral replication. Proviral CD8+ T-cell escape mutations
were undetectable at 1 year but accumulated at 2 years in Group M, while differences in SIV
non-Gag/Nef antigen-specific CD8+ T-cell responses between Groups M and N were evident
as early as 4 months post-infection. This implies that broadening of the CD8+ T-cell responses
in aviremic SIV controllers could serve as an indicator of the beginning of viral control failure.
All the Group M animals showed reduced numbers of non-Gag/Nef antigens targeted by CD8+
T cells at 2 years compared to those at 1 year (Fig 4). It is speculated that this might be because
viruses accumulate CD8+ T-cell escape mutations in those viral genome regions encoding
CD8+ T cell-targeted non-Gag/Nef antigens after 1 year post-infection.
In contrast, proviral mutations did not appear in Group N macaques even at 2 years post-
infection, indicating sustained viral control. These animals maintained Gag241–249-specific
CD8+ T cells which are considered important for viral control. The breadth and magnitude of
SIV-specific CD8+ T-cell responses remained constant in the chronic phase consistent with sta-
ble viral control in the presence of immunodominant Gag- and Nef-specific CD8+ T-cell
responses. In three Group N animals (R07-001, R07-006, and R07-003), Vif-specific CD8+ T-
cell responses became detectable at 2 years after infection, implying partial control failure by
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the Gag- and Nef-specific CD8+ T-cell responses. However, the remaining three vaccinated
controllers (R07-008, R09-009, and R09-010) in Group N showed no increased breadth of their
CD8+ T-cell targets, possibly reflecting the absence of escape mutants stimulating additional
CD8+ T-cell responses in the chronic phase.
Effective and broad CD8+ T-cell responses have been indicated to be important for the con-
trol of HIV/SIV replication [15,47–50]. Even if aviremic HIV/SIV control is achieved by virus-
specific potent CD8+ T-cell responses, residual viral replication may occur and allow accumu-
lation of CD8+ T-cell escape mutations in viral genome, possibly leading to eventual viremia
rebound. The present study addressed this issue after achievement of primary SIV control. The
rhCMV vector vaccine trial indicated lasting SIV control by persistent rhCMV-induced non-
classical CD8+ T-cell responses in rhesus macaques [44,51]. However, SIV controllers in the
present study are thought to have no CD8+ T-cell stimulators other than virus-derived antigens
post-infection. Thus, broadening of CD8+ T-cell responses is considered to be due to residual
viral replication as observed in Group M animals. Broader CD8+ T-cell responses would be
important for SIV control, but after achievement of a virus control condition, further broaden-
ing may indicate residual viral replication. In contrast, Group N animals, in particular three of
them (R07-008, R09-009, and R09-010), showed no broadening of their CD8+ T-cell targets,
which may represent a status of lasting SIV containment by CD8+ T cells.
The anti-CD8 antibody administration to the Group N macaque resulted in transient reap-
pearance of plasma viremia concomitant with CD8+ cell depletion, supporting the notion that
CD8+ T-cell responses are crucial for the stable SIV control observed. Sequence analysis of the
emergent virus indicated the existence of replication-competent viruses with multiple CD8+ T-
cell escape mutations, which can be controlled.
In summary, this study showed that increased breadth of virus-specific CD8+ T-cell
responses is detected before the accumulation of proviral CD8+ T-cell escape mutations and
viral control failure in aviremic SIV controllers. Broadly-reactive CD8+ T-cell responses may
be crucial for HIV control, but our results suggest that if the host could achieve the conditions
in which CD8+ T cells overwhelm HIV replication, non-broadening of CD8+ T-cell responses
represents a status of lasting HIV containment by CD8+ T cells.
Materials and Methods
Ethics statement
Animal experiments were carried out in Tsukuba Primate Research Center, National Institute
of Biomedical Innovation (NIBP; currently renamed National Institutes of Biomedical Innova-
tion, Health and Nutrition [NIBIOHN]) with the help of the Corporation for Production and
Research of Laboratory Primates after approval by the Committee on the Ethics of Animal
Experiments of NIBP (permission number: DS21-27, DS23-19, and DS25-31) under the guide-
line for animal experiments at NIBP and National Institute of Infectious Diseases in accor-
dance with the Guidelines for Proper Conduct of Animal Experiments established by Science
Council of Japan (http://www.scj.go.jp/ja/info/kohyo/pdf/kohyo-20-k16-2e.pdf). The experi-
ments were in accordance with the "Weatherall report for the use of non-human primates in
research" recommendations (https://royalsociety.org/topics-policy/publications/2006/
weatherall-report/)). Animals were housed in adjoining individual primate cages allowing
them to make sight and sound contact with one another for social interactions, where the tem-
perature was kept at 25°C with light for 12 hours per day. Animals were fed with apples and
commercial monkey diet (Type CMK-2, Clea Japan, Inc.). Blood collection, vaccination, virus
challenge, and anti-CD8 antibody treatment were performed under ketamine anesthesia.
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Animal experiments
We analyzed the chronic phase of SIVmac239 infection in ten Burmese rhesus macaques
(Macaca mulatta) possessing the MHC class I haplotype 90-120-Ia [32,33] (Table 1). These
animals were previously used for vaccination and challenge experiments [35,36]. One-third of
unvaccinated A+ animals controlled viremia after SIVmac239 infection in our previous study
[35], and unvaccinated macaques R06-037 and R07-001 and sham-vaccinated R07-006 were
used in the present study. Macaque R07-006 received a control prime-boost vaccine using a
DNA and a replication-incompetent F-deleted SeV (F[–]SeV) vector both expressing EGFP.
Three macaques R07-002, R07-003, and R07-008 received a DNA-prime/F(-)SeV-boost vac-
cine eliciting Gag241–249-specific CD8
+ T-cell responses. A pGag236-250-EGFP-N1 DNA and an
F(-)SeV-Gag236-250-EGFP vector both expressing an SIVmac239 Gag236-250 (IAGTTSSVDE-
QIQWM)-EGFP fusion protein were used for the single Gag241–249-epitope vaccine [35]. Three
macaques R03-018, R09-009, and R09-010 received a DNA-prime/F(-)SeV-boost vaccine elic-
iting Gag206–216-specific CD8
+ T-cell responses. A pGag202–216-EGFP-N1 DNA and an F(-)
SeV-Gag202–216-EGFP vector both expressing an SIVmac239 Gag202–216 (IIRDII-
NEEAADWDL)-EGFP fusion protein were used for the single Gag206–216-epitope vaccine [36].
Macaque R05-005 received both the Gag241–249-epitope and Gag206–216-epitope vaccines simul-
taneously. Animals received 5 mg of DNA intramuscularly and 6 weeks later received a single
intranasal boost with 6 x 109 cell infectious units of F(-)SeV vector. Approximately 3 months
after the F(-)SeV boost, animals were challenged intravenously with 1,000 50% tissue culture
infective doses of SIVmac239 [52]. For CD8+ cell depletion, macaque R09-009 received a single
subcutaneous inoculation of 10 mg/kg of body weight of monoclonal anti-CD8 antibody
(cM-T807) (NIH Nonhuman Primate Reagent Resource [R24 RR016001, N01 AI040101]) fol-
lowed by three intravenous inoculations of 5 mg/kg cM-T807 on days 3, 7, and 10 after the first
inoculation at week 108.
Proviral cDNA sequencing
Primary CD4+ T cells were prepared by negative selection from macaque PBMCs using a non-
human primate CD4+ T cell isolation kit (Miltenyi). Total cellular DNA was extracted from
CD4+ T cells using DNeasy extraction kit (QIAGEN). The DNA corresponding to the number
of CD4+ T cells indicated in S1 Table was subjected to nested PCR amplification of proviral
gag, vif, and nef cDNA fragments (nucleotide numbers [nt] 1231–2958 for gag, nt 4829–7000
for vif, and nt 8677–10196 for nef in SIVmac239 [accession number M33263]) for direct
sequencing using dye terminator chemistry and an automated DNA sequencer (Applied Bio-
systems) as previously described [25]. For macaques R06-037, R05-005, R07-001, and R07-006
at 2 years, total cellular DNAs were extracted not directly from CD4+ T cells but after 8 days of
culture described below. Dominant non-synonymous mutations were determined. For virus
recovery, 0.5–2 x 106 CD4+ T cells were cultured in the presence of 10 ng/ml human interleu-
kin-7 (IL-7) (Miltenyi) and 10 ng/ml human IL-15 (Miltenyi) for 8 days. Then, viral RNA was
extracted from supernatants of CD4+ T-cell culture using the High Pure Viral RNA kit (Roche
Diagnostics) and subjected to reverse transcription and nested PCR (RT-PCR) amplification of
viral gag cDNA fragments.
Analysis of antigen-specific CD8+ T-cell responses
Wemeasured virus-specific CD8+ T-cell frequencies by flow cytometric analysis of gamma
interferon (IFN-γ) induction after specific stimulation as described previously [53]. Autologous
herpesvirus papio-immortalized B-lymphoblastoid cell lines (B-LCLs) were pulsed with indi-
vidual SIVmac239 epitope-coding peptides (at a final concentration of 1–5 μM) or peptide
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pools (at a final concentration of 1–2 μM for each peptide) using panels of overlapping peptides
spanning the entire SIVmac239 Gag, Pol, Vif, Vpx, Vpr, Tat, Rev, Env, and Nef amino acid
sequences (Sigma-Aldrich Japan) for 1 hour. PBMCs were cocultured with these pulsed
B-LCLs in the presence of GolgiStop (monensin, BD) for 6 hours. Intracellular IFN-γ staining
was performed with a CytofixCytoperm kit (BD) and fluorescein isothiocyanate (FITC)-conju-
gated anti-human CD4 (BD), peridinin chlorophyll protein (PerCP)-conjugated anti-human
CD8 (BD), allophycocyanin-Cy7 (APC-Cy7)-conjugated anti-human CD3 (BD), and phycoer-
ythrin (PE)-conjugated anti-human IFN-γmonoclonal antibodies (Biolegend). In the flow
cytometric analysis, PBMCs were gated in Forward Scatter-Side Scatter dot plots and B-LCLs
were excluded. A representative gating schema for flow cytometric analysis is shown in S2 Fig.
Specific T-cell frequencies were calculated by subtracting nonspecific IFN-γ+ T-cell frequencies
from those after peptide-specific stimulation. Specific T-cell frequencies lower than 100 per
million PBMCs were considered negative.
Statistical analysis
Statistical analyses were performed with Prism software version 4.03 with significance levels set
at a P value of<0.0500 (GraphPad Software, Inc.). Comparisons between groups were made
using non-parametric tests.
Accession numbers
SIVmac239 proviral DNA: M33263.
Supporting Information
S1 Fig. Sequences of proviral nef cDNAs amplified from PBMCs at 2 years after SIV chal-
lenge in macaques R07-001 and R07-003.
(TIF)
S2 Fig. A representative gating schema for flow cytometric analysis.
(TIF)
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